SEMA7A and ductal breast carcinoma in situ: To test our hypothesis that a function blocking anti-SEMA7A antibody could decrease DCIS invasion via changes to macrophage localization and collagen structure, we treated mice with established MCF10DCIS tumors using our novel mouse monoclonal antibody that targets SEMA7A (SmAbH1) or an IgG control and measured tumor invasiveness at 4 weeks when MCF10DCIS tumors begin to progress to IDC (22).